Key Financial Results
All figures shown in the chart above are for the trailing 12 month (TTM) period
Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) exceeded analyst estimates by 1.4%.
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 24% growth forecast for the Biotechs industry in China.
Performance of the Chinese Biotechs industry.
The company's shares are up 2.6% from a week ago.
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Yantai Zhenghai Biotechnology, and understanding this should be part of your investment process.
Find out whether Yantai Zhenghai Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Read more from the original source:
Yantai Zhenghai Biotechnology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Recommendation and review posted by G. Smith
